Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2015, Article ID 215015, 10 pages
http://dx.doi.org/10.1155/2015/215015
Research Article

Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, Ethiopia

1Armauer Hansen Research Institute, P.O. Box 1005, Jimma Road, Addis Ababa, Ethiopia
2Aklilu Lemma Institute of Pathobiology, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia

Received 25 February 2015; Revised 14 May 2015; Accepted 18 May 2015

Academic Editor: Vincent Jarlier

Copyright © 2015 Minwuyelet Maru et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Global Tuberculosis Report 2014, World Health Organization, Geneva, Switzerland, 2014.
  2. World Health Organization, “Drug-resistant TB surveillance & response supplement,” Global Tuberculosis Report, 2014. View at Google Scholar
  3. World Health Organization, Global Tuberculosis Report 2013, World Health Organization, Geneva, Switzerland, 2013.
  4. E. M. Streicher, B. Müller, V. Chihota et al., “Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa,” Infection, Genetics and Evolution, vol. 12, no. 4, pp. 686–694, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Müller, S. Borrell, G. Rose, and S. Gagneux, “The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis,” Trends in Genetics, vol. 29, no. 3, pp. 160–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Abubakar, M. Zignol, D. Falzon et al., “Drug-resistant tuberculosis: time for visionary political leadership,” The Lancet Infectious Diseases, vol. 13, no. 6, pp. 529–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Andrews, N. S. Shah, D. Weissman, A. P. Moll, G. Friedland, and N. R. Gandhi, “Predictors of multidrug-and extensively drug-resistant tuberculosis in a high HIV prevalence community,” PLoS ONE, vol. 5, no. 12, Article ID e15735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Nathanson, P. Nunn, M. Uplekar et al., “MDR tuberculosis—critical steps for prevention and control,” The New England Journal of Medicine, vol. 363, no. 11, pp. 1050–1058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. World Health Organization, Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response, World Health Organization, Geneva, Switzerland, 2010, http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
  10. C. Demay, B. Liens, T. Burguière et al., “SITVITWEB—a publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology,” Infection, Genetics and Evolution, vol. 12, no. 4, pp. 755–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Weniger, J. Krawczyk, P. Supply, D. Harmsen, and S. Niemann, “Online tools for polyphasic analysis of Mycobacterium tuberculosis complex genotyping data: now and next,” Infection, Genetics and Evolution, vol. 12, no. 4, pp. 748–754, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Tessema, A. Muche, A. Bekele, D. Reissig, F. Emmrich, and U. Sack, “Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five-year retrospective study,” BMC Public Health, vol. 9, article 371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Abate, B. Taye, M. Abseno, and S. Biadgilign, “Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia,” BMC Research Notes, vol. 5, article 462, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Seyoum, M. Demissie, A. Worku, S. Bekele, and A. Aseffa, “Prevalence and drug resistance patterns of Mycobacterium tuberculosis among new smear positive pulmonary tuberculosis patients in Eastern Ethiopia,” Tuberculosis Research and Treatment, vol. 2014, Article ID 753492, 7 pages, 2014. View at Publisher · View at Google Scholar
  15. S. D. Hamusse, M. Demissie, D. Teshome, and B. Lindtjørn, “Fifteen-year trend in treatment outcomes among patients with pulmonary smear-positive tuberculosis and its determinants in Arsi Zone, Central Ethiopia,” Global Health Action, vol. 7, 2014. View at Publisher · View at Google Scholar
  16. World Health Organization, Guideline for Surveillance of Drug Resistance in Tuberculosis, World Health Organization, Geneva, Switzerland, 4th edition, 2009.
  17. P. Kent and G. Kubica, Public Health Mycobacteriology: A Guide for the Level III Laboratory, U. S. Department of Health and Human Services, Centers for Disease Control, Atlanta, Ga, USA, 1985.
  18. B. van Klingeren, M. Dessens-Kroon, T. van der Laan, K. Kremer, and D. van Soolingen, “Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method,” Journal of Clinical Microbiology, vol. 45, no. 8, pp. 2662–2668, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. M. Parsons, R. Brosch, S. T. Cole et al., “Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis,” Journal of Clinical Microbiology, vol. 40, no. 7, pp. 2339–2345, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Kamerbeek, L. Schouls, A. Kolk et al., “Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology,” Journal of Clinical Microbiology, vol. 35, no. 4, pp. 907–914, 1997. View at Google Scholar · View at Scopus
  21. I. Vitol, J. Driscoll, B. Kreiswirth, N. Kurepina, and K. P. Bennett, “Identifying Mycobacterium tuberculosis complex strain families using spoligotypes,” Infection, Genetics and Evolution, vol. 6, no. 6, pp. 491–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. Ministry of Health, Guidelines for Clinical and Programmatic Management of TB, Leprosy and TB/HIV in Ethiopia, Ministry of Health, Addis Ababa, Ethiopia, 2012.
  23. J. A. Caminero, G. Sotgiu, A. Zumla, and G. B. Migliori, “Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 621–629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Müller, V. N. Chihota, M. Pillay et al., “Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa,” PLoS ONE, vol. 8, no. 8, Article ID e70919, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Hingley-Wilson, R. Casey, D. Connell et al., “Undetected multidrug-resistant tuberculosis amplified by first-line therapy in mixed infection,” Emerging Infectious Diseases, vol. 19, no. 7, pp. 1138–1141, 2013. View at Publisher · View at Google Scholar
  26. T. C. Rodwell, F. Valafar, J. Douglas et al., “Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations,” Journal of Clinical Microbiology, vol. 52, no. 3, pp. 781–789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. F. A. Post, P. A. Willcox, B. Mathema et al., “Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis,” Journal of Infectious Diseases, vol. 190, no. 1, pp. 99–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. D. Calver, A. A. Falmer, M. Murray et al., “Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa,” Emerging Infectious Diseases, vol. 16, no. 2, pp. 264–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. R. Kempker, A. S. Rabin, K. Nikolaishvili et al., “Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis,” Clinical Infectious Diseases, vol. 54, no. 6, pp. e51–e54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Stoffels, C. Allix-Béguec, G. Groenen et al., “From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-Year nationwide study,” PLoS ONE, vol. 8, no. 5, Article ID e63128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Shingadia and J. A. Seddon, “Epidemiology and disease burden of tuberculosis in children: a global perspective,” Infection and Drug Resistance, vol. 7, pp. 153–165, 2014. View at Publisher · View at Google Scholar
  32. B. Tessema, J. Beer, M. Merker et al., “Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: new phylogenetic lineages found in Northwest Ethiopia,” BMC Infectious Diseases, vol. 13, no. 1, article 131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. A. H. Kebede, Z. Alebachew, F. Tsegaye et al., “The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011,” The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 6, pp. 635–639, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. G. D. van der Spuy, R. M. Warren, M. Richardson, N. Beyers, M. A. Behr, and P. D. van Helden, “Use of genetic distance as a measure of ongoing transmission of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 41, no. 12, pp. 5640–5644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Verver, R. M. Warren, Z. Munch et al., “Proportion of tuberculosis transmission that takes place in households in a high-incidence area,” The Lancet, vol. 363, no. 9404, pp. 212–214, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Kompala, S. V. Shenoi, and G. Friedland, “Transmission of tuberculosis in resource-limited settings,” Current HIV/AIDS Reports, vol. 10, no. 3, pp. 264–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Reynolds and S. K. Heysell, “Understanding pharmacokinetics to improve tuberculosis treatment outcome,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 6, pp. 813–823, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. J. G. Pasipanodya, H. McIlleron, A. Burger, P. A. Wash, P. Smith, and T. Gumbo, “Serum drug concentrations predictive of pulmonary tuberculosis outcomes,” Journal of Infectious Diseases, vol. 208, no. 9, pp. 1464–1473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. G. Pasipanodya, S. Srivastava, and T. Gumbo, “Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy,” Clinical Infectious Diseases, vol. 55, no. 2, pp. 169–177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Cohen, P. D. van Helden, D. Wilson et al., “Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control,” Clinical Microbiology Reviews, vol. 25, no. 4, pp. 708–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. A. Yimer, M. Agonafir, Y. Derese, Y. Sani, G. A. Bjune, and C. Holm-Hansen, “Primary drug resistance to anti-tuberculosis drugs in major towns of Amhara region, Ethiopia,” APMIS, vol. 120, no. 6, pp. 503–509, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Tessema, J. Beer, F. Emmrich, U. Sack, and A. C. Rodloff, “Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia,” BMC Infectious Diseases, vol. 12, article 37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Basu, G. H. Frledland, J. Medlock et al., “Averting epidemics of extensively drug-resistant tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 18, pp. 7672–7677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. N. R. Gandhi, D. Weissman, P. Moodley et al., “Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa,” Journal of Infectious Diseases, vol. 207, no. 1, pp. 9–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. H. S. Cox, C. McDermid, V. Azevedo et al., “Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa,” PLoS ONE, vol. 5, no. 11, Article ID e13901, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. World Health Organization, Tuberculosis, World Health Organization, 2015, http://www.who.int/mediacentre/factsheets/fs104/en/.
  47. J. E. M. de Steenwinkel, M. T. Ten Kate, G. J. de Knegt et al., “Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 9, pp. 4937–4944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Klopper, R. M. Warren, C. Hayes et al., “Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa,” Emerging Infectious Diseases, vol. 19, no. 3, pp. 449–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Banerjee, E. Dubnau, A. Quemard et al., “inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis,” Science, vol. 263, no. 5144, pp. 227–230, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Müller, E. M. Streicher, K. G. P. Hoek et al., “inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?” International Journal of Tuberculosis and Lung Disease, vol. 15, no. 3, pp. 344–351, 2011. View at Google Scholar · View at Scopus
  51. A. Z. Reeves, P. J. Campbell, R. Sultana et al., “Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5′ untranslated region of whiB7,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 4, pp. 1857–1865, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. B. Georghiou, M. Magana, R. S. Garfein, D. G. Catanzaro, A. Catanzaro, and T. C. Rodwell, “Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review,” PLoS ONE, vol. 7, no. 3, Article ID e33275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. L. E. Via, S.-N. Cho, S. Hwang et al., “Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis,” Journal of Clinical Microbiology, vol. 48, no. 2, pp. 402–411, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Jugheli, N. Bzekalava, P. de Rijk, K. Fissette, F. Portaels, and L. Rigouts, “High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5064–5068, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. World Health Organization, WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households, WHO/HTM/TB/2009.419, World Health Organization, Geneva, Switzerland, 2009.